Urogen Pharma (NASDAQ:URGN) Insider Sells $350,100.00 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00. Following the transaction, the insider directly owned 129,763 shares of the company’s stock, valued at approximately $4,543,002.63. This trade represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Price Performance

Shares of URGN opened at $34.54 on Friday. The company’s 50-day moving average is $28.50 and its 200-day moving average is $23.36. The firm has a market capitalization of $1.68 billion, a PE ratio of -12.56 and a beta of 1.59. Urogen Pharma has a fifty-two week low of $12.73 and a fifty-two week high of $36.08.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. Analysts predict that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on URGN. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a report on Wednesday, June 3rd. Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Finally, LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma currently has an average rating of “Moderate Buy” and an average target price of $39.50.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Osaic Holdings Inc. boosted its stake in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after acquiring an additional 5,571 shares during the period. Finally, Nebula Research & Development LLC bought a new stake in shares of Urogen Pharma during the 2nd quarter valued at $162,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.